Marksans Pharma Q1 FY27 Earnings Call: Peak EBITDA Margin of 25.3%, Maintains 20-21% EBITDA Guidance

Marksans Pharma Ltd held its Q1 FY27 earnings call on August 12, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Record Revenue & Profitability

• Revenue of Rs.841 Cr in Q1 FY2026-2027, up 35.6% YoY, driven by broad-based geographic strength across all regions.
• EBITDA of Rs.213 Cr — highest ever — with margin expanding 919 bps YoY to 25.3% and 251 bps sequentially; management flagged this as above the guided full-year range.
• PAT of Rs.159.4 Cr, up 173.9% YoY; PAT margin improved to 18.4% from 9.3% in Q1 FY2025-2026 and from 17.4% in Q4 FY2025-2026.
• Gross profit of Rs.497.3 Cr; gross margin of 59.1% expanded 138 bps YoY and 478 bps sequentially, aided by favourable mix and operating leverage.
• Cash from operations of Rs.185 Cr; free cash flow of Rs.152 Cr after net capex of Rs.33 Cr in Q1 FY2026-2027.
• Working capital cycle improved to ~132 days from ~159 days in Q1 FY2025-2026 and 138 days in Q4 FY2025-2026, driven by inventory unwinding.
• R&D spend of Rs.23.2 Cr (2.8% of revenue), nearly double from Rs.12.1 Cr (2.0%) in Q1 FY2025-2026, reflecting intensified focus on differentiated dosage forms.

74.7% YoY Growth, Acquisition-Led Expansion

• UK & Europe delivered Rs.356 Cr in Q1 FY2026-2027, up 74.7% YoY — the highest ever quarterly revenue for the region, contributing ~42% of total revenue.
• UK business (ex-ClinicQ) posted >50% organic YoY growth in Q1 FY2026-2027, driven by strong RX and OTC demand.
• ClinicQ acquisition (Netherlands) effective 1 April 2026; contributed Rs.44 Cr in Q1 FY2026-2027; management guided ClinicQ revenue of Rs.150–Rs.175 Cr for FY2026-2027.
• Europe revenue guided at ~Rs.180 Cr for FY2026-2027; ClinicQ historically ~€10 Mn, expected to reach €14–15 Mn (~40% growth).
• Germany subsidiary expected to generate meaningful revenue from early Q3 FY2026-2027, while Ireland subsidiary revenue is expected only in FY2027-2028 due to pending registrations.
• Gross margin for Europe currently ~29% aided by low-cost inventory; management guided FY2026-2027 gross margin around 55–56%, citing fluid input costs from the war and inventory depletion as temporary headwinds.

US, ANZ & Portfolio Mix Dynamics

• North America revenue of Rs.377 Cr (~45% of revenue) in Q1 FY2026-2027, up 15.1% YoY, with single-digit price erosion in the RX portfolio; management expects momentum to strengthen in coming quarters.
• Australia/New Zealand revenue of Rs.88 Cr in Q1 FY2026-2027, up 53.7% YoY, in line with seasonal patterns following a strong Q4 FY2025-2026 Southern Hemisphere winter.
• US order book remains strong; management reaffirmed the long-term target of Rs.4,000 Cr revenue within the next two years (by ~FY2028-2029), driven by all geographies.
• US medium-term revenue target of USD 300 Mn set as the next benchmark, with a stretch goal of "USD 400 million over a five-year horizon" (management's >3-year target).
• US business mix expected to shift from a historical 90–95% OTC / 5–10% RX toward ~85% OTC / 15% RX, though OTC will remain the core strength.
• Existing scale and long-standing US customer relationships position the company as a preferred partner, enabling growth by increasing product count per customer.

Peak Q1 Margins, Guided Full-Year Moderation

• Q1 FY2026-2027 EBITDA margin of 25.3% exceeded the formal guidance band; management maintained FY2026-2027 revenue growth guidance of 15%–20% and EBITDA margin guidance of 20%–21%, citing geopolitical volatility as the reason for not revising upward.
• Management guided full-year FY2026-2027 EBITDA margin at ~21–22% (segment 9), implying moderation from Q1's 25.3% level; the lower end of the formal 20–21% range remains the stated floor.
• Gross margin of 59.1% in Q1 FY2026-2027 is expected to moderate; management guided a sustainable range of 55%–56% for FY2026-2027, citing war-related input cost volatility and inventory depletion.
• Around 65%–70% of sales volume is manufactured in India (up to 70% at the high end); backward integration is not actively pursued, though DMF-related IP has been developed and the CRAMS business model is being explored.
• R&D intensity increased to 2.8% of revenue in Q1 FY2026-2027 from 2.0% in Q1 FY2025-2026, with focus on differentiated and more expensive dosage forms to expand the portfolio across all geographies.
• Cash reserves of Rs.1,050+ Cr are predominantly in low-yield FDs (4–5% post-tax), creating a drag on the 20% reported ROCE for FY2025-2026; management remains risk-averse, prioritising deployment for inorganic strategies.

M&A, Capacity Expansion & 2030 Vision

• Management identified FY2026-2027 as the year to pursue inorganic growth, with a "decent sized ticket deal" possible across markets; the company held Rs.1,000+ Cr cash against a ~Rs.3,000 Cr revenue run rate as of Q1 FY2026-2027.
• Management gave visibility of "doubling revenue within the next five years" (implied baseline: ~Rs.3,000 Cr in FY2025-2026), with no explicit interim milestones provided.
• Management aims to become "a top global consumer healthcare company by 2030" through OTC brand creation, portfolio expansion, and resource investment.
• Management evaluating acquisition targets (greenfield or brownfield) for additional manufacturing capacity; expects need for another unit in India within 1–2 years to support the 3–5 year strategic plan, though acquisition pricing remains a key challenge.
• R&D efforts intensifying to "double the portfolio in every country over the next two to three years", focusing on differentiated and more expensive dosage forms (period partly unspecified).
• Goa Unit 2 generating Rs.50+ Cr revenue against a projected ~Rs.80 Cr, operating at 60–65% of target as of Q1 FY2026-2027; management expects the unit to ramp up gradually.

Growth Trajectory, Guidance & Geopolitical Headwinds

• Q2 and Q3 FY2026-2027 expected to be stronger than Q1, with Q3 anticipated as the strongest quarter; management expects momentum to build through FY2026-2027.
• Europe expansion targets ~Rs.1,000 Cr revenue "in the next 3-5 years" through acquisitions, building on the Netherlands and Germany deals; management noted M&A is unpredictable with no fixed timeline, but sufficient corpus is available.
• Management does not give significant weight to President Trump's threat of a 200% duty after two years, citing likely political changes before then; the option of ramping up US production remains open as a hedged commitment.
• Rest of World markets (Middle East, other non-Western) remain challenged by war and transport disruptions, though they contribute a small share of revenue; no material impact on overall guidance.
• Analyst Jugal Shah suggested 20–25% growth should be the "new normal", calling 15–20% conservative; management did not explicitly endorse this figure, maintaining the formal 15%–20% FY2026-2027 guidance.
• Large India acquisitions would require paying valuation multiples, potentially consuming Rs.200–400 Cr of cash; management remains open to such deals but cited pricing discipline.